Drug General Information (ID: DDIQ5O3FWE)
Drug Name			Interferon alfa-2a, Recombinant		Drug Info		Enalapril		Drug Info
Drug Type		Interferons				Small molecule
Therapeutic Class		Interferons				Antihypertensive Agents

Mechanism of Interferon alfa-2a, Recombinant-Enalapril Interaction (Severity Level: Moderate)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Interferon alfa-2a, Recombinant				Enalapril
Mechanism		Interferon alfa-2a				Increase the risk of granulocytopenia combined with Interferon alfa-2a
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Interferon alfa-2a, Recombinant and Enalapril

Recommended Action
Management		Until more information is available, close hematologic monitoring is recommended.

References
1	Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20. [PMID: 10516744]
2	Product Information. Vasotec (enalapril). Merck &amp Co, Inc, West Point, PA.
3	Casato M, Pucillo LP, Leoni M, et al. "Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity." Am J Med 99 (1995): 386-91